Live price temporarily unavailable.
Establishment Labs Holdings (ESTA) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $34.7M | $61.2M | $89.6M | $84.7M | $126.7M | $161.7M | $165.2M | $166.0M | $211.1M |
| Growth (year over year) | — | +76.5% | +46.3% | −5.5% | +49.6% | +27.6% | +2.1% | +0.5% | +27.1% |
| Gross profit | $17.7M | $36.1M | $54.9M | $52.5M | $85.4M | $106.6M | $107.0M | $109.5M | $146.3M |
| Gross margin | 51.0% | 59.0% | 61.3% | 62.0% | 67.4% | 65.9% | 64.8% | 66.0% | 69.3% |
| Operating income | −$20.0M | −$23.9M | −$30.9M | −$27.9M | −$25.1M | −$39.7M | −$65.0M | −$50.0M | −$39.0M |
| Operating margin | −57.6% | −39.0% | −34.5% | −33.0% | −19.8% | −24.5% | −39.4% | −30.1% | −18.5% |
| Net income | −$34.9M | −$21.1M | −$38.1M | −$38.1M | −$41.1M | −$75.2M | −$78.5M | −$84.6M | −$51.1M |
| Net margin | −100.6% | −34.5% | −42.6% | −45.0% | −32.5% | −46.5% | −47.5% | −51.0% | −24.2% |
| EPS (diluted) | −$3.41 | −$1.22 | −$1.86 | −$1.63 | −$1.72 | −$3.08 | −$3.07 | −$3.00 | −$1.72 |
| Balance sheet | |||||||||
| Cash and equivalents | $10.9M | $52.6M | $37.7M | $84.5M | $53.4M | $66.4M | $40.0M | $90.3M | $75.6M |
| Total assets | $57.1M | $116.6M | $116.5M | $156.4M | $139.5M | $211.1M | $268.6M | $346.8M | $357.2M |
| Total liabilities | $62.1M | $47.1M | $76.9M | $81.4M | $88.8M | $219.2M | $250.2M | $293.7M | $333.6M |
| Long-term debt | — | — | $48.1M | $49.8M | $51.9M | $175.5M | $188.7M | $219.6M | $247.5M |
| Shareholders' equity | −$5.01M | $69.5M | $39.6M | $75.0M | $50.7M | −$8.19M | $18.4M | $53.1M | $23.5M |
| Cash flow | |||||||||
| Operating cash flow | −$32.0M | −$33.9M | −$30.0M | −$12.5M | −$27.5M | −$52.2M | −$88.5M | −$58.5M | −$50.9M |
| Capital expenditure | $901.0K | $1.73M | $6.29M | $2.11M | $2.42M | $2.85M | $7.91M | $6.11M | $6.05M |
| Free cash flow | −$32.9M | −$35.6M | −$36.3M | −$14.6M | −$30.0M | −$55.0M | −$96.4M | −$64.6M | −$56.9M |
| Share buybacks | $4.51M | $0 | — | — | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $40.2M | $44.5M | $41.4M | $51.3M | $53.8M | $64.6M | $59.9M | $67.5M |
| Growth (year over year) | +4.5% | +41.0% | +11.3% | +16.3% | +33.7% | +45.2% | +44.7% | +31.7% |
| Gross profit | $25.7M | $30.5M | $27.8M | $35.3M | $37.7M | $45.5M | $42.3M | $47.7M |
| Gross margin | 63.9% | 68.5% | 67.2% | 68.8% | 70.1% | 70.5% | 70.7% | 70.6% |
| Operating income | −$13.1M | −$18.7M | −$16.9M | −$14.1M | −$4.03M | −$3.93M | −$6.51M | −$4.29M |
| Operating margin | −32.7% | −41.9% | −41.0% | −27.5% | −7.5% | −6.1% | −10.9% | −6.4% |
| Net income | −$16.7M | −$34.5M | −$20.7M | −$16.6M | −$11.1M | −$2.62M | −$13.4M | −$11.7M |
| Net margin | −41.5% | −77.6% | −50.1% | −32.3% | −20.7% | −4.0% | −22.3% | −17.4% |
| EPS (diluted) | −$0.59 | −$1.21 | −$0.70 | −$0.57 | −$0.38 | −$0.07 | −$0.45 | −$0.39 |
| Balance sheet | ||||||||
| Cash and equivalents | $39.7M | $90.3M | $69.2M | $54.6M | $70.6M | $75.6M | $68.1M | $71.2M |
| Total assets | $282.7M | $346.8M | $333.4M | $329.7M | $338.9M | $357.2M | $351.0M | $351.9M |
| Total liabilities | $250.0M | $293.7M | $294.8M | $306.9M | $322.5M | $333.6M | $336.3M | $330.3M |
| Long-term debt | $194.4M | $219.6M | $220.3M | $221.1M | $246.5M | $247.5M | $248.6M | $261.7M |
| Shareholders' equity | $32.7M | $53.1M | $38.5M | $22.8M | $16.4M | $23.5M | $14.8M | $21.6M |
| Cash flow | ||||||||
| Operating cash flow | −$12.5M | −$20.7M | −$20.7M | −$18.8M | −$11.3M | −$162.0K | −$4.31M | −$16.6M |
| Capital expenditure | $1.47M | $531.0K | $753.0K | $1.62M | $1.85M | $1.82M | $1.85M | $3.66M |
| Free cash flow | −$13.9M | −$21.3M | −$21.5M | −$20.4M | −$13.1M | −$1.99M | −$6.16M | −$20.3M |
From Establishment Labs Holdings's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Establishment Labs Holdings in our feed yet.